Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether intracoronary abciximab bolus application
with subsequent 12 hour intravenous infusion in addition to primary percutaneous coronary
intervention is beneficial for patients with STEMI in comparison to standard i.v. bolus
application with respect to 90-day mortality, reinfarction and new congestive heart failure.
Phase:
Phase 3
Details
Lead Sponsor:
University of Leipzig
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments